HIV Vaccines

Manufacturing Agreement Reached For Plasmid DNA-Based Vaccine

Published in Gene Therapy Weekly, July 5th, 2001

pAllliance, a strategic alliance between QIAGEN N.V. (Nasdaq: QGENF; Neuer Markt: QIA; Easdaq: QGEN), DSM Biologics, Valentis Inc. (Nasdaq: VLTS), and the Wyeth-Lederle Vaccines (WLV), a business unit of the American Home Products Corporation (NYSE: AHP), announced an agreement pursuant to which the pAlliance will manufacture plasmid DNA-based vaccine materials for WLV's clinical trials.

The pAlliance members believe that this agreement represents one of the largest agreements for pAlliance since the it was initiated in early 1999 and started supplying contract manufacturing services for DNA-based therapeutics and vaccines to what is today a significant group of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-07-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry